Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

Inclusion Criteria:

Patients must meet all of the following criteria at Baseline:

• Patients initiating Hyrimoz® treatment.

• Patients with a confirmed diagnosis (following local recommendations) of one ofthese indications: CD or UC.

• Patients ≥ 18 years of age.

• Patient in whom the decision to initiate Hyrimoz® (naïve population) or to switch (switch population) from reference adalimumab to Hyrimoz® was accorded with hisphysician before the proposal to participate in the study.

• Patients meeting one of the following criteria:

• Referred to as "switched patients": Patients treated continuously withadalimumab (other than Hyrimoz®) for at least 6 months, with an indication forcontinuing treatment with adalimumab at any therapeutic dose (physician'sdecision) and who have controlled stable disease for at least 3 months beforestudy enrollment (according to the physician's criteria).

• Referred to as "biologic-naive patients": Patients who had an inadequateresponse or contraindications to conventional therapy with no exposure to anybiological medicine and targeted therapies and started Hyrimoz® as a first-linebiologic therapy according to the summary of product characteristics (SmPC).

• Patients able to complete and understand the self-administered questionnaires.

• Patients who have been informed and have provided a signed written consent as perlocal regulations prior to participation in the study

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

• Patients enrolled in an ongoing interventional study.

• Patients with any contraindications to Hyrimoz® according to the SmPC.

• Patients at imminent risk of scheduled intestinal surgery (stenosis, strictures,internal fistula).

• Use of any investigational drug in last 6 months prior to enrollment.

• Patient received any biological medicine or targeted therapy, in case of "biologic-naive patient ",

• Patient received adalimumab for less than 6 months or have controlled disease forless than 3 months, in case of "switched patient".